Adverse drug reactions to atezolizumab in combination with bevacizumab in hepatocellular carcinoma patients: an analysis of the food and drug administration adverse event reporting system database.

ABSTRACT:

Purpose

The objective of the study is to systematically identify and evaluate the adverse drug reactions (ADRs) associated with the combination therapy of systematically and bevacizumab in patients with unresectable hepatocellular carcinoma (HCC).

Patients and methods

Data were extracted from the Food and Drug Administration (FDA) Adverse Event Reporting System FDA Adverse Event Reporting System database. Disproportionality analysis was conducted using the reporting odds ratio (ROR), proportional reporting ratio (PRR) and Bayesian confidence propagation neural network (BCPNN) of information components (IC). Time-to-onset (TTO) profiles were analyzed using the Weibull shape parameter (WSP) test, while cumulative incidences were assessed using the Kaplan‒Meier method. Valuable

SUBMITTER: He W 

PROVIDER: S-EPMC11885501 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature